Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
暂无分享,去创建一个
A. Hauschild | D. Schadendorf | F. Egberts | R. Dummer | M. Lacouture | A. Scherag | G. McArthur | G. Long | R. Carvajal | M. Kashani-Sabet | K. Busam | E. Livingstone | A. Sucker | L. Zimmer | U. Hillen | S. Goldinger
[1] D. Schadendorf,et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Nagai,et al. Vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[3] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] K. Flaherty,et al. BRAF targeted therapy changes the treatment paradigm in melanoma , 2011, Nature Reviews Clinical Oncology.
[5] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[6] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[7] K. Flaherty,et al. Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] V. Sondak,et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. , 2011, Cancer research.
[9] N. Rosen,et al. Mutant BRAF melanomas--dependence and resistance. , 2011, Cancer cell.
[10] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[11] Damien Kee,et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.
[12] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[13] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[14] A. Aplin,et al. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. , 2010, Cancer research.
[15] V. Sondak,et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy , 2010, British Journal of Cancer.
[16] M. Brown,et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. , 2010 .
[17] David B Solit,et al. Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response , 2010, Clinical Cancer Research.
[18] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[19] Karen Cichowski,et al. Drug discovery: Inhibitors that activate , 2010, Nature.
[20] Chao Zhang,et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.
[21] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.
[22] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Reis-Filho,et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. , 2009, Cancer cell.
[24] Ultan McDermott,et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. , 2008, Cancer research.
[25] C. Petti,et al. In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation , 2008, Modern Pathology.
[26] Sreenath V. Sharma,et al. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.
[27] G. Powis,et al. The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling , 2006, Cancer Chemotherapy and Pharmacology.
[28] M. Rao,et al. Cyclin D1 expression in melanocytic lesions of the skin. , 2005, Annals of diagnostic pathology.
[29] M. Martinka,et al. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Becker,et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis , 2004, Journal of carcinogenesis.
[31] A. Gottlieb,et al. The insulin-like growth factor 1 receptor is expressed by epithelial cells with proliferative potential in human epidermis and skin appendages: correlation of increased expression with epidermal hyperplasia. , 1996, The Journal of investigative dermatology.
[32] J. Lott. Vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[33] D. Pinkel,et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. , 2007, The Journal of investigative dermatology.
[34] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.